×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

South Korea Porcine Vaccines Market

ID: MRFR/Pharma/48722-HCR
200 Pages
Rahul Gotadki
October 2025

South Korea Porcine Vaccines Market Research Report By Type (Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines), By Disease Indication (PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine influenza, Aujeszky's disease (AD), Porcine Circovirus Associated Disease (PCVAD), Others) and By End-user (Veterinary Hospitals, Hog Production Farm) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

South Korea Porcine Vaccines Market Infographic
Purchase Options

South Korea Porcine Vaccines Market Summary

As per Market Research Future analysis, the South Korea porcine vaccines market size was estimated at 48.0 USD Million in 2024. The South Korea porcine vaccines market is projected to grow from 50.98 USD Million in 2025 to 93.0 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 6% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The South Korea porcine vaccines market is experiencing robust growth driven by increasing demand and regulatory support.

  • The market is witnessing a rising demand for vaccination as awareness of animal health escalates.
  • Government initiatives and regulations are fostering a favorable environment for vaccine adoption.
  • Technological advancements in vaccine development are enhancing efficacy and safety profiles.
  • Key market drivers include increasing awareness of animal health and rising pork consumption, which are propelling market growth.

Market Size & Forecast

2024 Market Size 48.0 (USD Million)
2035 Market Size 93.0 (USD Million)
CAGR (2025 - 2035) 6.2%

Major Players

Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

South Korea Porcine Vaccines Market Trends

The porcine vaccines market in South Korea is currently experiencing notable developments. These are driven by advancements in veterinary medicine and increasing awareness of animal health. The government has implemented stringent regulations to ensure the safety and efficacy of vaccines, which has led to a rise in research and development activities. This focus on innovation is likely to enhance the quality of vaccines available, thereby improving herd immunity and reducing the incidence of diseases among swine populations. Furthermore, the growing demand for pork products in both domestic and international markets is pushing producers to adopt better health management practices, including vaccination programs. In addition, the porcine vaccines market is influenced by the increasing prevalence of swine diseases, which necessitates effective vaccination strategies. The South Korean government, along with industry stakeholders, is actively promoting vaccination as a critical component of disease control. This collaborative effort appears to be fostering a more robust market environment, where producers are encouraged to invest in vaccination to safeguard their livestock. As the market evolves, it is anticipated that technological advancements, such as the development of novel vaccine formulations and delivery methods, will further shape the landscape of the porcine vaccines market in South Korea.

Rising Demand for Vaccination

There is an increasing recognition among swine producers regarding the importance of vaccination in maintaining herd health. This trend is driven by the need to enhance productivity and ensure food safety, as consumers become more health-conscious.

Government Initiatives and Regulations

The South Korean government is actively promoting vaccination through various initiatives aimed at improving animal health standards. Stringent regulations are being enforced to ensure the quality and safety of vaccines, which is likely to bolster market growth.

Technological Advancements in Vaccine Development

Innovations in vaccine technology are emerging, with a focus on developing more effective and safer vaccine formulations. These advancements may lead to improved immunization strategies, thereby enhancing disease control in swine populations.

South Korea Porcine Vaccines Market Drivers

Rising Pork Consumption

The increasing consumption of pork in South Korea is significantly impacting the porcine vaccines market. As pork remains a staple protein source for many South Koreans, the demand for healthy and disease-free pigs is paramount. This trend is expected to drive farmers to invest more in vaccination programs to ensure the health of their livestock. Recent statistics indicate that pork consumption in South Korea has risen by approximately 3% annually, leading to a corresponding increase in the need for effective vaccines. Consequently, the porcine vaccines market is likely to expand as producers seek to enhance the health and productivity of their herds to meet consumer demand.

Advancements in Vaccine Technology

Technological advancements in vaccine development are playing a crucial role in shaping the porcine vaccines market. Innovations such as recombinant vaccines and adjuvant technologies are enhancing the efficacy and safety of vaccines available for swine. These advancements not only improve the immune response in pigs but also reduce the incidence of adverse effects, making vaccination more appealing to farmers. The introduction of new vaccine formulations is expected to increase market penetration, as producers are more likely to adopt products that demonstrate superior performance. As a result, the porcine vaccines market is anticipated to witness substantial growth driven by these technological improvements.

Increasing Awareness of Animal Health

The growing awareness regarding animal health and welfare in South Korea is driving the porcine vaccines market. Farmers and producers are increasingly recognizing the importance of vaccination in preventing diseases that can affect swine populations. This heightened awareness is likely to lead to a rise in vaccination rates, thereby boosting demand for porcine vaccines. According to recent data, the swine population in South Korea is approximately 10 million, and with the increasing focus on biosecurity measures, the market for vaccines is projected to grow at a CAGR of around 5% over the next few years. This trend indicates a shift towards more proactive health management practices in the livestock sector. Such practices are essential for maintaining productivity and profitability in the porcine industry.

Economic Incentives for Disease Prevention

Economic factors are significantly influencing the porcine vaccines market in South Korea. The rising costs associated with disease outbreaks in swine herds are prompting farmers to invest in preventive measures, including vaccination. By vaccinating their livestock, producers can mitigate the financial risks associated with disease management and loss of productivity. Recent analyses suggest that the economic impact of swine diseases can lead to losses exceeding $100 million annually in South Korea. Consequently, the porcine vaccines market is likely to benefit from this economic rationale, as farmers seek to protect their investments and ensure the sustainability of their operations.

Regulatory Support for Vaccination Programs

Regulatory frameworks in South Korea are increasingly supportive of vaccination programs, which is beneficial for the porcine vaccines market. The government has implemented policies that encourage the use of vaccines to control and prevent swine diseases. This regulatory support is likely to enhance the adoption of vaccination practices among farmers, thereby increasing the overall market size. Furthermore, initiatives aimed at educating farmers about the benefits of vaccination are expected to foster a more robust market environment. As a result, the porcine vaccines market is projected to grow as compliance with vaccination regulations becomes more prevalent among livestock producers.

Market Segment Insights

By Type: Inactivated vaccines (Largest) vs. Live attenuated vaccines (Fastest-Growing)

In the South Korea porcine vaccines market, the distribution of market share among different vaccine types reveals inactivated vaccines as the dominant segment, capturing a significant portion of the market. Following closely are live attenuated vaccines, which have started to gain traction due to their effective immunization capacity and lower production costs. The other types, including toxoid, recombinant, conjugate, and DNA vaccines, hold smaller market shares but contribute significantly to the overall diversity of vaccine options available. Growth trends indicate a strong future for live attenuated vaccines, driven by increasing awareness of porcine health and the need for effective disease management. Additionally, advancements in vaccine technology and increased R&D investments are propelling these vaccines to the forefront. The inactivated vaccines remain critical, but their growth is steady rather than rapid, as new innovations emerge within the sector, targeting enhanced immune responses and production efficiencies.

Inactivated vaccines (Dominant) vs. Recombinant vaccines (Emerging)

Inactivated vaccines hold a dominant position in the South Korea porcine vaccines market, characterized by their ability to evoke strong immune responses without the risk of causing disease in the vaccinated population. Their widespread usage is attributed to the reliability and safety they offer, making them a preferred choice among livestock producers. On the other hand, recombinant vaccines represent an emerging segment, showing promise in terms of specificity and efficiency. They utilize cutting-edge biotechnology to create targeted immune responses, appealing to modern practices in veterinary medicine. As these technologies advance, recombinant vaccines are expected to carve out a larger share of the market, particularly among producers seeking innovative solutions to enhance herd health.

By Disease Indication: PED (Largest) vs. PRRS (Fastest-Growing)

In the South Korea porcine vaccines market, the distribution of market share among disease indications reveals that Porcine Epidemic Diarrhea (PED) is the largest segment, holding a significant portion of the market. Other critical contributors include PRRS, Swine Influenza, Aujeszky's Disease, and Porcine Circovirus Associated Disease (PCVAD), each playing a substantial role in shaping the landscape of porcine vaccines as they target specific health challenges within swine populations. Looking towards growth trends, PRRS has gained traction as the fastest-growing segment due to increasing awareness of its impact on the swine industry. The rising prevalence of these diseases alongside advancements in vaccination technology provides a robust backdrop for market expansion, as stakeholders seek to enhance disease management and improve herd health profitability.

PED (Dominant) vs. PCVAD (Emerging)

Porcine Epidemic Diarrhea (PED) stands out as the dominant disease indication, significantly impacting pig health and productivity. The extensive adoption of PED vaccines highlights their critical role in minimizing outbreaks and ensuring swine welfare. In contrast, Porcine Circovirus Associated Disease (PCVAD) is emerging, driven by evolving understanding and recognition of its effects on livestock. With advancements in vaccine formulations and delivery systems, the PCVAD sector exhibits potential for substantial growth. Together, these segments illustrate the dynamic nature of the South Korea porcine vaccines market, catering to specific health threats that demand focused and innovative solutions.

By End-user: Veterinary Hospitals (Largest) vs. Hog Production Farm (Fastest-Growing)

In the South Korea porcine vaccines market, Veterinary Hospitals hold the largest share, reflecting their critical role in managing the health and well-being of pigs. They serve as primary points for vaccine administration, diagnostics, and treatment, thus significantly influencing the market dynamics. Conversely, Hog Production Farms are emerging as the fastest-growing segment due to their increasing demand for efficient herd management practices and a surge in large-scale operations seeking to enhance productivity. Current growth trends in this segment are driven by heightened awareness of swine diseases and the necessity for effective vaccination regimes. Moreover, advancements in vaccine technology and a focus on biosecurity measures are encouraging more farms to adopt comprehensive vaccination strategies. As livestock operators strive for increased production efficiency, the reliance on both Veterinary Hospitals and Hog Production Farms is set to intensify, reflecting an evolving market landscape.

Veterinary Hospitals (Dominant) vs. Hog Production Farm (Emerging)

Veterinary Hospitals play a dominant role in the South Korea porcine vaccines market, acting as essential hubs for animal healthcare. They are equipped with skilled professionals and advanced diagnostics tools, ensuring that pigs receive timely vaccinations and treatments. Their established trust with livestock owners contributes to their sustained market share, making them vital in controlling disease outbreaks. On the other hand, Hog Production Farms are recognized as an emerging segment, increasingly incorporating vaccination programs into their operational protocols. These farms prioritize biosecurity and health management, promoting the use of vaccines as a fundamental part of their production practices. As the demand for high-quality pork rises, the focus on vaccination within these farms is likely to grow, enhancing their importance in the market.

Get more detailed insights about South Korea Porcine Vaccines Market

Key Players and Competitive Insights

The porcine vaccines market in South Korea is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Zoetis (US), Merck Animal Health (US), and Boehringer Ingelheim (DE) are at the forefront, leveraging their extensive research capabilities and established market presence to drive growth. These companies appear to focus on developing advanced vaccine formulations and enhancing their distribution networks, which collectively fosters a dynamic competitive environment. The emphasis on innovation and strategic collaborations among these firms suggests a trend towards more sophisticated vaccine solutions tailored to local needs.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market seems moderately fragmented, with several players vying for market share while also collaborating on research initiatives. This fragmentation allows for a diverse range of products and services, catering to the specific needs of the South Korean market, while the influence of major players remains substantial.

In October Zoetis (US) announced the launch of a new vaccine specifically targeting Porcine Reproductive and Respiratory Syndrome (PRRS), a significant advancement in the fight against this prevalent disease. This strategic move not only reinforces Zoetis's commitment to innovation but also positions the company to capture a larger share of the market by addressing a critical health issue affecting swine production. The introduction of this vaccine is likely to enhance the overall health of pig populations, thereby improving productivity for farmers.

In September Merck Animal Health (US) expanded its partnership with local veterinary institutions to enhance research on vaccine efficacy and safety. This collaboration appears to be a strategic effort to leverage local expertise and ensure that their products meet the specific health challenges faced by the South Korean swine industry. By investing in local research, Merck is likely to strengthen its market position and foster trust among local producers, which could lead to increased adoption of its vaccines.

In August Boehringer Ingelheim (DE) launched a digital platform aimed at providing farmers with real-time data on vaccine performance and animal health. This initiative seems to reflect a broader trend towards digitalization in the agricultural sector, where data-driven insights can significantly enhance decision-making processes. By integrating technology into their offerings, Boehringer Ingelheim is likely to differentiate itself from competitors and provide added value to its customers.

As of November the competitive trends in the porcine vaccines market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing product offerings. The shift from price-based competition to a focus on technological advancements and supply chain reliability is evident. Moving forward, companies that prioritize innovation and adaptability in their strategies are likely to emerge as leaders in this evolving market.

Key Companies in the South Korea Porcine Vaccines Market include

Industry Developments

The South Korea Porcine Vaccines Market has witnessed notable developments, particularly with advances in vaccine technology aimed at enhancing swine health and productivity. Recent initiatives from companies like Zoetis, Merck Animal Health, and Boehringer Ingelheim have focused on innovative vaccine formulations to control prevalent swine diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS). In terms of market dynamics, a significant partnership was formed in August 2023 between Virbac and a leading South Korean research institution to bolster R&D in advanced vaccine strategies.

Additionally, Hipra has expanded its production capacity in South Korea to meet rising domestic and export demands, reflecting the increasing awareness of biosecurity among swine farmers. The market has been positively influenced by a 15% annual growth rate in the adoption of vaccination programs in swine, as reported by the Ministry of Agriculture, Food and Rural Affairs. In July 2023, Phibro Animal Health announced an acquisition of a local biotech firm, enhancing its product portfolio in the region. These trends underscore South Korea's commitment to strengthening its animal health landscape, driven by innovation and collaboration among leading companies.

Future Outlook

South Korea Porcine Vaccines Market Future Outlook

The Porcine Vaccines Market in South Korea is projected to grow at a 6.2% CAGR from 2025 to 2035, driven by increasing disease outbreaks and advancements in vaccine technology.

New opportunities lie in:

  • Development of customized vaccine formulations for specific regional diseases.
  • Expansion of e-commerce platforms for vaccine distribution.
  • Investment in R&D for next-generation vaccine delivery systems.

By 2035, the porcine vaccines market is expected to achieve substantial growth and innovation.

Market Segmentation

South Korea Porcine Vaccines Market Type Outlook

  • Inactivated vaccines
  • Live attenuated vaccines
  • Toxoid vaccines
  • Recombinant vaccines
  • Conjugate vaccines
  • DNA vaccines

South Korea Porcine Vaccines Market End-user Outlook

  • Veterinary Hospitals
  • Hog Production Farm

South Korea Porcine Vaccines Market Disease Indication Outlook

  • PED (Porcine Epidemic Diarrhea)
  • PRRS (Porcine Reproductive & Respiratory Syndrome)
  • Swine influenza
  • Aujeszky's disease (AD)
  • Porcine Circovirus Associated Disease (PCVAD)
  • Others

Report Scope

MARKET SIZE 2024 48.0(USD Million)
MARKET SIZE 2025 50.98(USD Million)
MARKET SIZE 2035 93.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.2% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR)
Segments Covered Type, Disease Indication, End-user
Key Market Opportunities Advancements in vaccine technology enhance disease prevention in the porcine vaccines market.
Key Market Dynamics Rising demand for innovative porcine vaccines driven by regulatory changes and technological advancements in South Korea.
Countries Covered South Korea
Leave a Comment

FAQs

What is the projected market size of the South Korea Porcine Vaccines Market by 2035?

The South Korea Porcine Vaccines Market is projected to be valued at 120.0 million USD by the year 2035.

What is the expected CAGR for the South Korea Porcine Vaccines Market from 2025 to 2035?

The expected CAGR for the South Korea Porcine Vaccines Market from 2025 to 2035 is 8.687%.

How much is the market valued at for inactivated vaccines in 2024?

In 2024, the market for inactivated vaccines is valued at 15.0 million USD.

Which type of porcine vaccines is anticipated to have the highest market value by 2035?

By 2035, inactivated vaccines are anticipated to have the highest market value at 37.0 million USD.

Who are the major players in the South Korea Porcine Vaccines Market?

Major players in the market include Hipra, Phibro Animal Health, Virbac, and Zoetis among others.

What is the expected value of live attenuated vaccines in 2035?

The expected value of live attenuated vaccines in 2035 is 28.0 million USD.

What opportunities exist for growth in the South Korea Porcine Vaccines Market?

There are significant opportunities for growth driven by advancements in vaccine technology and increasing demand for porcine health.

What challenges may impact the South Korea Porcine Vaccines Market?

Challenges may include regulatory hurdles and evolving disease threats affecting pig populations.

What is the market size for toxoid vaccines in 2024?

The market size for toxoid vaccines in 2024 is valued at 9.0 million USD.

How do the market values compare between recombinant and conjugate vaccines by 2035?

By 2035, recombinant vaccines are valued at 18.0 million USD while conjugate vaccines are valued at 15.0 million USD.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions